These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12039922)
21. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. Vaishampayan UN; Marur S; Heilbrun LK; Cher ML; Dickow B; Smith DW; Al Hasan SA; Eliason J J Urol; 2009 Jul; 182(1):317-23. PubMed ID: 19447430 [TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937 [TBL] [Abstract][Full Text] [Related]
23. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group. Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S; Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893 [TBL] [Abstract][Full Text] [Related]
24. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. O'connor T; Rustum Y; Levine E; Creaven P Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973 [TBL] [Abstract][Full Text] [Related]
25. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Bekaii-Saab T; Hill M; Campbell A; Kosuri K; Thomas J; Villalona-Calero M Cancer Chemother Pharmacol; 2010 Apr; 65(5):863-9. PubMed ID: 19657639 [TBL] [Abstract][Full Text] [Related]
26. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ; Oncology; 2004; 67(2):117-22. PubMed ID: 15539915 [TBL] [Abstract][Full Text] [Related]
27. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
28. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Orditura M; Martinelli E; Galizia G; Carlomagno C; Aurilio G; Vecchione L; Lieto E; De Placido S; Catalano G; Ciardiello F; De Vita F Ann Oncol; 2006 Oct; 17(10):1529-32. PubMed ID: 16873436 [TBL] [Abstract][Full Text] [Related]
29. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217 [TBL] [Abstract][Full Text] [Related]
30. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Michalaki V; Gennatas S; Gennatas K Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694 [TBL] [Abstract][Full Text] [Related]
31. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Mikhail S; Lustberg MB; Ruppert AS; Mortazavi A; Monk P; Kleiber B; Villalona-Calero M; Bekaii-Saab T Cancer Chemother Pharmacol; 2015 Nov; 76(5):1005-12. PubMed ID: 26416564 [TBL] [Abstract][Full Text] [Related]
32. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918 [TBL] [Abstract][Full Text] [Related]
33. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952 [TBL] [Abstract][Full Text] [Related]
34. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223 [TBL] [Abstract][Full Text] [Related]
35. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704 [TBL] [Abstract][Full Text] [Related]
36. A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism. Safra T; Bernstein Molho R; Menzcher J; Inbar M; Grisaru D; Levy T Chemotherapy; 2009; 55(4):298-302. PubMed ID: 19521076 [TBL] [Abstract][Full Text] [Related]
37. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S; Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235 [TBL] [Abstract][Full Text] [Related]
38. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117 [TBL] [Abstract][Full Text] [Related]
39. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688 [TBL] [Abstract][Full Text] [Related]
40. A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine. Hirawat S; Kolitz J; Lichtman SM; Allen SL; Villani G; Gonzales A; Fricano M; Budman DR Cancer Invest; 2007; 25(3):148-53. PubMed ID: 17530484 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]